恆大(03333.HK)向浙江建設等轉讓杭州水晶城項目 涉36.6億元人民幣
中國恆大(03333.HK)公佈,附屬公司以總代價爲36.6億元人民幣(下同)擬向浙江省浙建房地產集團、浙江建設(002761.SZ)轉讓在建項目杭州水晶城,預期集團就出售事項將會錄得收益約2.16億元,收益部份對價將用於抵償集團就其於杭州地區項目(其中包括水晶城項目)欠付受讓方(浙江建設)9.21億元工程款,其餘出售事項所得款項將作爲集團一般營運金。
中國恆大指流動性問題對項目開發和進度造成負面影響。這次交易將在建的商業物業和需自持的商業物業變現,扣除抵償工程款後所得相關款項、資產將作爲集團一般營運資金。
恆大已自3月21日起停牌。(ta/w) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.